These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

770 related items for PubMed ID: 16199254

  • 1. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G.
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G.
    Support Care Cancer; 2005 Dec; 13(12):975-86. PubMed ID: 15871033
    [Abstract] [Full Text] [Related]

  • 3. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K, Plosker GL.
    Pharmacoeconomics; 2008 Dec; 26(3):251-68. PubMed ID: 18282018
    [Abstract] [Full Text] [Related]

  • 4. Bisphosphonates for breast cancer.
    Pavlakis N, Schmidt R, Stockler M.
    Cochrane Database Syst Rev; 2005 Jul 20; (3):CD003474. PubMed ID: 16034900
    [Abstract] [Full Text] [Related]

  • 5. [Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].
    Schivazappa C, Berto P, Baldini E, Barni S, Dauria G, Cortesi E.
    Recenti Prog Med; 2008 Jan 20; 99(1):27-31. PubMed ID: 18389868
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
    Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.
    J Med Econ; 2012 Jan 20; 15(4):712-23. PubMed ID: 22409231
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer.
    James N, Pirrie S, Pope A, Barton D, Andronis L, Goranitis I, Collins S, McLaren D, O'Sullivan J, Parker C, Porfiri E, Staffurth J, Stanley A, Wylie J, Beesley S, Birtle A, Brown J, Chakraborti P, Russell M, Billingham L.
    Health Technol Assess; 2016 Jul 20; 20(53):1-288. PubMed ID: 27434595
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH.
    Clin Breast Cancer; 2005 Jun 20; 6(2):125-31. PubMed ID: 16001990
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study.
    Xie F, Hopkins R, Burke N, Tarride JE, Goeree R.
    Hosp Pract (1995); 2012 Apr 20; 40(2):131-7. PubMed ID: 22615087
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic.
    Cristino J, Finek J, Jandova P, Kolek M, Pásztor B, Giannopoulou C, Qian Y, Brezina T, Lothgren M.
    J Med Econ; 2017 Aug 20; 20(8):799-812. PubMed ID: 28485692
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.